Cetero Research. (11/16/10). "Press Release: Cetero Research Expands Business Development in Europe. Respected Industry Leader to Enhance Cetero’s Success in the EU". Cary, NC.

	Region	Europe
	Organisation	Cetero Research (Group)
	Organisation 2	Icon plc
	Group	Icon plc (Group)
	Product	laboratory services
	Person	Pullen, Marcus (Cetero Research 201011– Senior Director BusDev Europe before Icon Development Solutions BusDev)
	Person 2	Capicchioni, John (Cetero Research 201011 President Business Development)

Cetero Research, the leading early-stage contract research organization (CRO), today announced the appointment of Marcus Pullen as Senior Director, Business Development, based in the United Kingdom. Pullen will be Cetero's first business development representative in Europe for new business opportunities.

With more than 15 years of experience working for international CROs, Pullen has extensive knowledge of early-stage clinical trials. He has spent his career based in the United Kingdom, building relationships across Europe and Asia.

"We are excited to have Marcus as part of the Cetero team," said John Capicchioni, Vice President, Business Development, of Cetero Research. "We are seeing extraordinary business opportunities and growth across Europe given the comprehensive scope of early-stage services that Cetero provides. With Marcus in Europe, more clients will gain an understanding of the services that Cetero offers in clinical pharmacology, bioanalytical, scientific affairs and development consultancy services."

Prior to joining Cetero, Pullen served as Senior Director of Business Development at ICON Development Solutions. As a senior industry professional with a track record of high performance, Pullen's main responsibilities were to advance business opportunities with new clients in the biotech and pharmaceutical industries and manage key accounts within the company's existing client base.

"European pharmaceutical, biotech and generic companies value CROs that implement industry-leading best practices," said Troy W. McCall, Ph.D., CEO of Cetero Research. "Cetero emphasizes strong science and innovative study designs that are supported by world-class quality and service. We are very fortunate to have him as our first European business development representative."

About Cetero Research

Cetero Research is the leading early-stage contract research organization (CRO). With more than 25 years of experience from its founding companies, Cetero has conducted more than 10,000 clinical pharmacology studies - more than any other CRO. Cetero's proven track record allows the company to provide flexible and high-quality drug-development services. The company's time-tested systems produce consistent and reliable data clients can trust. Cetero's clinical research expertise consists of traditional early-stage, healthy-volunteer clinical pharmacology and bioavailability studies, as well as specialty Phase Ia/b trials in patients. Its bioanalytical services support clinical, preclinical drug and biomarker analysis for small and large molecules. For more information, visit www.cetero.com, or call 877.7CETERO.

# # #

For more information, please contact:
April Johnson
Vice President, Business Relationship Management
Cetero Research
Direct Line: 919-468-4214
Email: april.johnson@cetero.com

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

Cetero Research. (11/16/10). "Press Release: Cetero Research Expands Business Development in Europe. Respected Industry Leader to Enhance Cetero’s Success in the EU". Cary, NC.

More documents for Cetero Research (Group)